PharmaPoint: Hemophilia A and B - Japan Drug Forecast and Market Analysis to 2022, New Report Launched

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Overall prevalence of hemophilia A among Japanese patients older than age 50 is expected to decline over the forecast period. In addition, Publisher believes that opportunities for premium pricing will be limited in Japan, further constraining growth of the Japanese hemophilia market.

Scope

• Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in Japan from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting Japan Hemophilia A and B market.

 Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2012-2022 in Japan

Spanning over 129 pages, 48 Tables and 3 Figures, “PharmaPoint: Hemophilia A and B - Japan Drug Forecast and Market Analysis to 2022” report covering Disease Overview, Disease Management, ompetitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Inquire about this report: http://www.marketresearchreports.com/globaldata/pharmapoint-hemophilia-and-b-japan-drug-forecast-and-market-analysis-2022

Browse more Releated Reports at:

PharmaPoint: Hemophilia A and B - Argentina Drug Forecast and Market Analysis to 2022 visit at- http://www.marketresearchreports.com/globaldata/pharmapoint-hemophilia-and-b-argentina-drug-forecast-and-market-analysis-2022